Aldosterone Receptors

Cytoplasmic proteins that specifically bind aldosterone and mediate its cellular effects. The aldosterone-bound receptor acts in the nucleus to regulate the transcription of specific segments of DNA.

Also Known As:

Networked: 271 relevant articles (24 outcomes, 62 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Krum, Henry: 6 articles (07/2006 - 10/2002)
2.	Sica, Domenic A: 5 articles (05/2014 - 07/2003)
3.	Pitt, Bertram: 5 articles (05/2009 - 05/2002)
4.	Bakris, George L: 4 articles (05/2014 - 11/2004)
5.	Tang, W H Wilson: 4 articles (09/2012 - 12/2005)
6.	Boccanelli, Alessandro: 4 articles (10/2010 - 05/2005)
7.	Masson, Serge: 4 articles (01/2009 - 12/2002)
8.	Latini, Roberto: 4 articles (01/2009 - 12/2002)
9.	Bauersachs, Johann: 4 articles (06/2006 - 06/2003)
10.	Liew, Danny: 4 articles (05/2004 - 10/2002)

Related Diseases

1.	Heart Failure 07/01/2004 - "Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms." 02/27/2013 - "In this randomized controlled trial, long-term aldosterone receptor blockade improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life in patients with heart failure with preserved ejection fraction. " 12/01/2005 - "Aldosterone receptor antagonists in the medical management of chronic heart failure." 10/01/2010 - " echocardiographic study AREA IN-CHF evaluated, for the first time, the effectiveness of aldosterone receptor blocker therapy in patients with mild to moderate heart failure (NYHA class II). " 05/01/2005 - "These landmark studies showed that aldosterone receptor blockade prolongs survival in advanced and postinfarction heart failure, respectively. "
2.	Hypertension (High Blood Pressure) 12/01/2012 - "This is the case also for the efficacy of aldosterone receptor antagonists as an add-on treatment of resistant hypertension. " 01/01/2011 - "The long-term efficacy of aldosterone-receptor antagonists (ARAs) as add-on treatment in uncontrolled hypertension has not yet been reported. " 07/01/2006 - "Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension." 02/01/2001 - "This is the first study to demonstrate that aldosterone receptor antagonism normalizes blood pressure, prevents upregulation of vascular ET-1, restores NO-mediated endothelial dysfunction, and thus, may advance as a novel and specific therapeutic approach in 11beta-HSD2-deficient hypertension." 02/01/2013 - "Add-on therapy with aldosterone receptor antagonists has been reported to lower blood pressure (BP) in patients with uncontrolled hypertension. "
3.	Myocardial Infarction 01/01/2013 - "Few studies have reported the effect of aldosterone receptor antagonist (ARA) on myocardial remodeling after acute myocardial infarction (AMI). " 11/01/2011 - "[Aldosterone receptor antagonist use after myocardial infarction. " 04/01/2009 - "Aldosterone receptor antagonism reduces mortality and improves post-myocardial infarction (MI) remodeling. " 02/01/2008 - "Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction." 08/01/2001 - "Effect of a selective aldosterone receptor antagonist in myocardial infarction."
4.	Respiratory Sounds (Crackle) 03/01/2002 - "Beneficial effects of aldosterone-receptor blockade on mortality (RALES trial) appear to be mediated be extrarenal and renal mechanisms. " 11/06/2002 - "In the Randomized ALdactone Evaluation Study (RALES), spironolactone, an aldosterone receptor antagonist, significantly reduced mortality in patients with severe CHF. " 10/01/2010 - "The clinical efficacy of aldosterone inhibition in heart failure was proved in two important clinical trials, RALES and EPHESUS, which demonstrated a reduction in mortality with aldosterone receptor blocker therapy in patients with severe and post-MI heart failure.The" 05/01/2010 - "One trial of spironolactone (Randomised Aldactone Evaluation Study, RALES) and one of canrenone (Antiremodelling Effect of Aldosterone receptors blockade with canrenone In mild Chronic Heart Failure, AREA IN-CHF) comprised general HF, but data were available for an ischaemic subgroup. " 07/01/2002 - "The recent RALES (Randomized Aldactone Evaluation Study) trial demonstrated early reduction in morbidity and mortality using spironolactone, an aldosterone receptor antagonist, in combination with angiotensin converting enzyme (ACE) inhibitor and loop diuretic, in patients with heart failure. "
5.	Proteinuria 08/01/2010 - "In limited human studies, aldosterone receptor antagonism is associated with decreased proteinuria and improved glomerular filtration rate. " 03/01/2007 - "Combining ACEi and aldosterone receptor blockade (aldoRB) in proteinuric renal disease reduces proteinuria, but effects on proteinuria-induced renal damage are unknown. " 11/01/2007 - "Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats." 03/01/2006 - "The reduction in proteinuria among patients who were taking spironolactone-containing regimens was sustained at 6 and 12 mo. This study suggests that aldosterone receptor blockade offers a valuable adjuvant treatment when used with ACEI therapy for the reduction of proteinuria. " 12/01/2006 - "These results suggest that aldosterone receptor blockade combined with ACEI and ARB therapy offers a valuable adjuvant treatment for the reduction of proteinuria in patients with Alport syndrome as in those with other chronic kidney diseases. "

Related Drugs and Biologics

1.	eplerenone (Inspra)
2.	Spironolactone (Aldactone)
3.	Aldosterone
4.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
5.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
6.	Angiotensin Receptor Antagonists
7.	Angiotensin Receptors (Angiotensin II Receptor)
8.	Angiotensin II
9.	Renin
10.	Hormones

Related Therapies and Procedures

1.	Cardiac Resynchronization Therapy
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Surgical Instruments (Clip)
4.	Adrenalectomy
5.	Ligation